LUPIN
0 deep-dives · 13 policy notes
What has moved LUPIN
13 dated calls from the policy coverage · 7 positive · 1 negative · 5 watch
- Positive2026-10-19inferred
The US is the largest market for all four, and a 100% secondary tariff on all Indian goods was the single largest unhedged risk in their US revenue line
Policy Pulse - Modi / India Govt - 19 Oct 2026 - Positive2026-10-16inferred
Pharmaceuticals are the largest single Indian export category to the US and the one where a tariff differential against competing suppliers is worth most per unit; the first-tranche text is the mechanism that delivers it
Policy Pulse - Ministries & Regulators - 16 Oct 2026 - Watch2026-10-15inferred
Section 113 applies to "all goods," so Indian pharmaceutical exports are formally in scope — but the provision is conditioned on new purchases, and no target list has been published
Policy Pulse - Global Spillover - 15 Oct 2026 - Negative2026-10-13inferred
Section 113 attaches to all goods, not just energy-linked ones, so US-bound generic exporters carry headline risk on top of the existing tariff stack
Policy Pulse - Global Spillover - 13 Oct 2026 - Watch2026-10-13inferred
The October 14 DGHS deadline for the anti-cancer drug positive list carries a proposed 30% trade-margin cap, which is a price intervention into the oncology channel rather than a volume change
Policy Pulse - Ministries & Regulators - 13 Oct 2026 - Positive2026-10-13inferred
The PM explicitly cited India's 20% share of global generics as strategic weight rather than as an export statistic
Policy Pulse - Modi / India Govt - 13 Oct 2026 - Watch2026-10-09
Manufacturer selling prices are untouched, so the direct earnings impact is minimal; the reputational and volume effect on cancer portfolios is the only channel
Policy Pulse - Ministries & Regulators - 09 Oct 2026 - Positive2026-10-07
Pharma is a named market-access category; EFTA tariff elimination lowers the cost of Swiss/EU intermediates
Policy Pulse - Modi / India Govt - 07 Oct 2026 - Positive2026-10-05
Pharma is one of four export categories the Prime Minister named for Swiss market access, and life sciences is one of six named investment targets. Switzerland is a branded-pharma market where Indian generic filings have a long approval runway
Policy Pulse - Modi / India Govt - 05 Oct 2026 - Watch2026-10-01inferred
Indian pharma retains the Section 232 generic exemption negotiated earlier, but remains inside the Section 301 overcapacity universe. A new duty tier on Indian manufacturing would hit the generic export book ⚠️ inferred from the investigation's scope, not from any named company
Policy Pulse - Global Spillover - 01 Oct 2026 - Watch2026-10-01
Large-cap and mid-cap pharma is not the target of the scheme — these names largely exceed the MSME eligibility test, so the read-through is thematic rather than financial. Separately, this complex remains exposed to the pending Section 301 overcapacity investigation covering 16 economies including India and to the September 29 expansion of Section 232 medical-device tariffs. Neither is a PRIP effect ⚠️ sector-only, weak stock inference
Policy Pulse - Ministries & Regulators - 01 Oct 2026 - Positive2026-09-30
All are US-facing with complex-generics or specialty pipelines in or adjacent to the exempt categories; the generics carve-out is the larger structural relief
Policy Pulse - Global Spillover - 30 Sep 2026 - Positive2026-09-30inferred
Pharma is India's largest single export line to the US and generics already sit outside Section 232; a preferential-tariff outcome is the sector's largest single policy lever ⚠️ inferred
Policy Pulse - Modi / India Govt - 30 Sep 2026
Mentioned in Policy Pulse
Policy Pulse - Modi / India Govt - 19 Oct 2026
India's 100% tariff tail risk is gone: the Graham Act waiver removes the secondary duty that would have hit every Indian shipment, putting IOC, BPCL and HINDPETRO back on Russian crude without an export penalty, while WAAREEENER faces the one duty that was not waived.
Policy Pulse - Modi / India Govt - 13 Oct 2026
PM Modi told the Bloomberg New Economy Forum on October 13 that the routes of globalisation have become chokepoints, naming supply chains, energy, critical minerals and payments, a framing that maps to TCS, INFY, SUNPHARMA and HINDCOPPER. The PMO named no company, so every mapping is inferred.
Policy Pulse - Ministries & Regulators - 09 Oct 2026
The RBI raised daily CRR maintenance to 99% and lined up Rs 25,000 crore of bond sales, negative for rate-sensitive NBFCs and bond-funded lenders; SEBI mandated a colour-coded credit risk-o-meter, positive for CRISIL and ICRA; and a 30% cap on cancer-drug trade margins lifted Apollo Hospitals and Fortis while TCS led a 3% Nifty IT rally.
Policy Pulse - Modi / India Govt - 07 Oct 2026
PM Modi inaugurates India Mobile Congress 2026 on October 8 at Yashobhoomi and met the GSMA board, with Starlink declaring its India launch ready after building 20 gateway sites, a mixed signal for BHARTIARTL and IDEA and a positive for INDUSTOWER, TEJASNET and HFCL on densification and backhaul. Modi and Swiss President Parmelin address the second India-EFTA Prosperity Summit with the USD 100 billion TEPA investment target, the direct read-through for NESTLEIND and ABB. The Rural Development Ministry notified 375 permissible works under VB-G RAM G in a 41 percent expansion supporting PNCINFRA, HINDUNILVR and M&M.
Policy Pulse - Modi / India Govt - 05 Oct 2026
PM Modi and Swiss President Guy Parmelin signed five agreements at Hyderabad House on Monday, pairing expanded market access for Indian agriculture, pharma, textiles and engineering goods with a $100 billion EFTA investment target and fresh channels in biotech, life sciences, banking and insurance - a positive read-through for SUNPHARMA, WELSPUNLIV and NESTLEIND - alongside a Migration and Mobility Partnership and a Young Professionals Agreement. The PMO named no company, so every mapping here is inferred and confidence-marked. Forward catalyst: Chennai Metro Phase II's first 14 km on October 11.
Policy Pulse - Global Spillover - 01 Oct 2026
G20 trade ministers endorsed a Milwaukee Framework on steel overcapacity as Greer put the MFN principle itself up for review, while a Section 301 overcapacity probe covering 16 economies including India remains the unexercised risk to SUNPHARMA, WELSPUNLIV and BHARATFORG. Brent went back above $100 on China's fuel-export halt, lifting XOM and CVX against DAL and CCL, the US 10-year held near 5.28% after its biggest quarterly gain since 1994, and Micron's blowout quarter drove a 2.9-3.3% Nikkei rally.
Policy Pulse - Ministries & Regulators - 01 Oct 2026
The Finance Ministry cut the diesel and ATF export levy for a second fortnight, positive for IOC, BPCL and RELIANCE, as GST crossed Rs 2 lakh crore for a third month and the manufacturing PMI hit a seven-month high of 55.1. SEBI cleared corporate bond index futures for the NSE, the AMCA prototype RFP closed on 30 October with LT, BEL, BHARATFORG, BEML and DATAPATTNS named in the three shortlisted consortia while HAL did not qualify, and the rupee closed at 96.31 into a live RBI hike risk on October 7.
Policy Pulse - Global Spillover - 30 Sep 2026
The G20 Trade Ministerial opened in Milwaukee on steel excess capacity, MFN erosion and forced labour - the same ground as the Section 301 tariffs under challenge at the Court of International Trade - while core PCE at 3.0% cut October Fed hike odds from 71% to 35% and eased the front end. Saudi Arabia restarted the East-West pipeline and Yanbu loadings, Gulf exports recovered to 23.3 mbpd with Brent near $103, and India kept 0% Section 232 tariffs on specialty drugs, supporting SUNPHARMA and DRREDDY.
Policy Pulse — Ministries & Regulators — 26 Aug 2026
RBI MPC holds repo at 5.25% with GDP raised to 6.7%; Piyush Goyal to visit US for G20 trade meet and USTR talks
Policy Pulse — Ministries & Regulators — 31 Jul 2026
India-US pharma deal exempts Indian generics from Section 232 (BUY SUNPHARMA, DRREDDY, CIPLA). SEBI Stock Brokers Regulations 2026. Nifty Pharma +0.7%.
Policy Pulse — Global Spillover — 24 Jul 2026
Strait of Hormuz crisis at peak — 13th night of US strikes, Iran rejects ceasefire, oil above 00. Generic drug tariff timeline begins Aug 1. Section 122 expiry relief for importers. Stock impact: BUY oil/gas/defence/renewables, SELL airlines/refiners/generic pharma.
Policy Pulse — Global Spillover — 23 Jul 2026
INFY Q1: +12% PAT, guidance trimmed, ADR -4.85%. INDIGO: ₹238cr net loss on fuel costs (85% rise). CIPLA: -39% PAT. Hormuz: 12th night, Brent near 8. IOC/MRPL halt Iraq loadings. Section 122 expiry tomorrow benefits Indian IT/Textiles. ONGC gains, refiners bleed.
Policy Pulse — Modi / India — 22 Jul 2026
Nifty below 24,000 on Brent 5, IOCs halt Iraq oil loadings due to Hormuz (ONGC gains, IOC/BPCL/HPCL pressured). Trump generic drug tariff crushes Sun Pharma, Lupin, Cipla. Nestlé, Bajaj Auto shine on stellar Q1. Bandhan Bank -19% on RoA cut.